All In Biotech

Drug Trial Radar · NCT03819153

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease

Last checked: Nov 19, 2026Latest source record: Mar 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,533 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,533

Actual

Start

Jun 17, 2019

Primary completion

Jan 9, 2024

Study completion Jan 9, 2024

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jan 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will get semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is decided by chance. Semaglutide is a medicine, doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine in a skin fold once a week. The study will close when there is enough information collected to show clear result of the study. The total time participants will be in this study is about 3 to 5 years, but it could be longer.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • SemaglutideDrug

    Participants are to inject semaglutide with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject semaglutide under their skin. Participants will inject semaglutide 1 time a week on the same day of the week. Participants' dose of semaglutide will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.

  • Placebo (semaglutide)Drug

    Participants are to inject placebo (semaglutide) with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject placebo (semaglutide) under their skin. Participants will inject placebo (semaglutide) 1 time a week on the same day of the week. Participants' dose of placebo (semaglutide) will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV DeathTime frame: From Week 0 up to Week 234

Locations

413 sites in 28 countries. Site status is shown where the registry gives one.

  • Dr. Terence Hart

    Tuscumbia, Alabama

  • California Inst Of Renal Res

    Chula Vista, California

  • John Muir Physician Network

    Concord, California

  • John Muir Physicians Network

    Concord, California

  • Valley Research

    Fresno, California

  • California Institute of Renal Research

    La Mesa, California

  • First Valley Med Grp Lancaster

    Lancaster, California

  • Clinical Trials Research_Sacramento

    Lincoln, California

  • VA Loma Linda Hlthcr Sys

    Loma Linda, California

  • Long Beach Center For Clinical Research

    Long Beach, California

  • VA Long Beach Healthcare System

    Long Beach, California

  • Academic Medical Research Institute

    Los Angeles, California

  • Valley Renal Medical Group Research

    Northridge, California

  • Desert Oasis Hlthcr Med Group

    Palm Springs, California

  • Saviers Medical Group

    Port Hueneme, California

  • Inland Empire Clin Trials LLC

    Rialto, California

  • Sierra Clinical Research

    Roseville, California

  • California Research Foundation

    San Diego, California

  • N America Res Inst - San Dimas

    San Dimas, California

  • NorCal Endocrinology and Internal Medicine

    San Ramon, California

  • Lundquist Inst-Biomed Innovtn

    Torrance, California

  • San Fernando Valley Hlth Inst

    West Hills, California

  • Rocky Mount Reg VA Med-DN

    Aurora, Colorado

  • Creekside Endocrine Associates, PC

    Denver, Colorado

  • BayCare Medical Group - Endocrinology

    Clearwater, Florida

  • Horizon Rs Grp, Coral Gbls

    Coral Gables, Florida

  • Cesar Figueroa M.D. P.A.

    Delray Beach, Florida

  • Northeast Research Institute

    Fleming Island, Florida

  • Palmetto Medical General Plaza

    Hialeah, Florida

  • Encore Medical Research LLC

    Hollywood, Florida

  • Homestead Associates In Research

    Homestead, Florida

  • Life Spring Research

    Miami, Florida

  • Oceane 7 Medical & Research Center, Inc.

    Miami, Florida

  • International Physicians Research

    Miami, Florida

  • San Marcus Res Clin Miami Lakes

    Miami Lakes, Florida

  • Floridian Clinical Research, LLC

    Miami Lakes, Florida

  • South Broward Research LLC

    Miramar, Florida

  • Suncoast Clinical Research, Inc.

    New Port Richey, Florida

  • Hanson Clinical Research Center

    Port Charlotte, Florida

  • Northeast Research Institute

    Saint Augustine, Florida

Showing 40 of 413 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.